CIC bioGUNE , Bizkaia Technology Park, Building 801A, 48170 Derio, Spain.
IBMC-Instituto de Biologia Celular e Molecular , Campo Alegre 823, 4150 Porto, Portugal.
J Med Chem. 2017 Jul 13;60(13):5749-5758. doi: 10.1021/acs.jmedchem.7b00428. Epub 2017 Jun 16.
Several strategies against Alzheimer disease (AD) are directed to target Aβ-peptides. The ability of transthyretin (TTR) to bind Aβ-peptides and the positive effect exerted by some TTR stabilizers for modulating the TTR-Aβ interaction have been previously studied. Herein, key structural features of the interaction between TTR and the Aβ(12-28) peptide (3), the essential recognition element of Aβ, have been unravelled by STD-NMR spectroscopy methods in solution. Molecular aspects related to the role of the TTR stabilizer iododiflunisal (IDIF, 5) on the TTR-Aβ complex have been also examined. The NMR results, assisted by molecular modeling protocols, have provided a structural model for the TTR-Aβ interaction, as well as for the ternary complex formed in the presence of IDIF. This basic structural information could be relevant for providing light on the mechanisms involved in the ameliorating effects of AD symptoms observed in AD/TTR animal models after IDIF treatment and eventually for designing new molecules toward AD therapeutic drugs.
几种针对阿尔茨海默病(AD)的策略旨在针对 Aβ 肽。转甲状腺素蛋白(TTR)结合 Aβ 肽的能力以及一些 TTR 稳定剂对调节 TTR-Aβ 相互作用的积极影响已被先前研究过。在此,通过 STD-NMR 光谱法在溶液中研究了 TTR 与 Aβ(12-28)肽(3)之间相互作用的关键结构特征,Aβ 的必需识别元件。还检查了与 TTR 稳定剂碘代二氟尼柳(IDIF,5)在 TTR-Aβ 复合物中作用相关的分子方面。NMR 结果,辅以分子建模方案,为 TTR-Aβ 相互作用以及在 IDIF 存在下形成的三元复合物提供了结构模型。这些基本结构信息可能有助于阐明 IDIF 治疗后在 AD/TTR 动物模型中观察到的 AD 症状改善作用所涉及的机制,并最终设计针对 AD 治疗药物的新分子。